Table 1.
Patient characteristics
| Patients in present study (n = 912) | Patients with HOXB13 expression data (n = 866) | Original cohort (n = 1,780) | |
|---|---|---|---|
| Tumor diameter | |||
| ≤20 mm | 697 (79) | 661 (79) | 1,393 (81) |
| >20 mm | 189 (21) | 181 (21) | 323 (19) |
| Unavailable | 26 | 24 | 64 |
| Estrogen receptor status | |||
| Positive | 686 (78) | 651 (77) | 1,183 (80) |
| Negative | 198 (22) | 190 (23) | 296 (20) |
| Unavailable | 28 | 25 | 301 |
| Progesterone receptor status | |||
| Positive | 415 (52) | 401 (52) | 590 (48) |
| Negative | 380 (48) | 366 (48) | 627 (52) |
| Unavailable | 117 | 99 | 563 |
| Tamoxifen treatment | |||
| Yes | 473 (52) | 447 (52) | 886 (50) |
| No | 439 (48) | 419 (48) | 894 (50) |
Data presented as number of patients (%). Tumor and treatment characteristics of the patients included in the original cohort, patients in the present study and patients in the present study with successful HOXB13 protein expression scoring.